Ireland
--:--IST
Recruiting Not applicable

Efficiency of Virtual Reality Exposure Therapy in the Management of Body Dysmorphic Disorders in Female Adolescents With Anorexia Nervosa

NCT04107870 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-06-20
Last updated
2023-03-08

Condition(s) studied

Anorexia Nervosa

Investigational drug(s) / intervention(s)

Virtual Reality Exposure Therapy sessionsPsychomotor therapy sessions

Virtual Reality Exposure Therapy sessions: Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations

Psychomotor therapy sessions: Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.

Study summary

Anorexia nervosa is defined in DSM V as a quantitative and qualitative dietary restriction resulting in significant weight loss, intense fear of weight gain, altered weight and body shape perception (body dysmorphic disorder) and low self-esteem influenced by weight or body shape. Body dysmorphic disorder is the most difficult symptom to manage in anorexia nervosa and its persistence is a factor associated with relapse.

Virtual reality exposure therapy has proven its effectiveness in the management of post-traumatic stress disorder in the military and is a widely used therapy. The effectiveness of this treatment using new technologies has not yet been studied for the treatment of body dysmorphic disorder in anorexia nervosa and is not used routinely. It could represent an interesting alternative to the physical approach in psychomotor therapy, traditionally offered to patients suffering from anorexia nervosa. It is important to evaluate the effectiveness of virtual reality exposure therapy in the management of body dysmorphic disorder in patients with anorexia nervosa by comparing these two care techniques.

Eligibility

Sex
FEMALE
Min age
13 Years
Max age
17 Years
Healthy volunteers
No
Inclusion criteria : * Female adolescents aged 13 to 18 * with a diagnosis of anorexia nervosa of all types (including purgative and hyperphagic) according to the DSM-V * French as first language * agreed to participate in the study * parental authority holders accepting her participation in the study * affiliated to a social security system Patients will not be included in the study: * with a somatic severity criterion: * Total aphagia * Body mass index (BMI) \< 14kg/m² for those over 17 years of age, BMI \< 13.2kg/m² for those aged 15-16 and BMI \< 12.7kg/m² for those aged 13-14. * Confusion * Bradycardia \<40/min, Tachycardia * Blood pressure \< 80/50mmHg * Hypothermia \<35.5°C * Severe metabolic disorders: hypokalemia \< 2.5 mmol/l, hyponatremia \< 125mmol/l or hypernatremia \> 150 mmol/l, hypophosphoremia \< 0.5 mmol/l * Acetonuria, hypoglycemia \< 0.6g/l * Creatinine elevation \> 100micromol/l * Cytolysis \> 4N * Leuconeutropenia \<1000/mm3 * Thrombocytopenia \<6000000/mm3 * Suicide attempt in the last month before inclusion * Receiving benzodiazepine treatment outside the prescription limits. * Psychotic patients or patients with psychoactive substance addiction according to MINI KID criteria (Sheehan DV et al. Reliability and validity of the Mini International Neuropsychiatric Interview for children and adolescents (MINI Kid). J Clin Psychiatry 2010;71(3):313-326).

Primary outcome measure(s)

  • Body Shape Questionnaire — 12 months
    The Body Shape Questionnaire (BSQ) measures concerns about body shape. The BSQ can be divided into 4 sub scores: "avoidance and social shame of body exposure", "body dissatisfaction with lower body parts", "use of laxatives and vomiting to reduce body dissatisfaction" and "inappropriate cognitions and behaviours to control weight".

Trial sites (1)

FacilityCityRegionStatus
Damien JOLLY Reims France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04107870 on ClinicalTrials.gov ↗ ← All trials in France